Literature DB >> 32481373

Regional variation in states' naloxone accessibility laws in association with opioid overdose death rates-Observational study (STROBE compliant).

Hyo-Sun You1, Jane Ha2, Cyra-Y Kang3, Leeseul Kim3, Jinah Kim3, Jay J Shen4, Seong-Min Park5, Sung-Youn Chun3, Jinwook Hwang6, Takashi Yamashita7, Se Won Lee8, Georgia Dounis9, Yong-Jae Lee10, Dong-Hun Han4,11, David Byun12, Ji Won Yoo13, Hee-Taik Kang1,4,14.   

Abstract

Though overall death from opioid overdose are increasing in the United States, the death rate in some states and population groups is stabilizing or even decreasing. Several states have enacted a Naloxone Accessibility Laws to increase naloxone availability as an opioid antidote. The extent to which these laws permit layperson distribution and possession varies. The aim of this study is to investigate differences in provisions of Naloxone Accessibility Laws by states mainly in the Northeast and West regions, and the impact of naloxone availability on the rates of drug overdose deaths.This cross-sectional study was based on the National Vital Statistics System multiple cause-of-death mortality files. The average changes in drug overdose death rates between 2013 and 2017 in relevant states of the Northeast and West regions were compared according to availability of naloxone to laypersons.Seven states in the Northeast region and 10 states in the Western region allowed layperson distribution of naloxone. Layperson possession of naloxone was allowed in 3 states each in the Northeast and the Western regions. The average drug overdose death rates increased in many states in the both regions regardless of legalization of layperson naloxone distribution. The average death rates of 3 states that legalized layperson possession in the West region decreased (-0.33 per 100,000 person); however, in states in the West region that did not allow layperson possession and states in the Northeast region regardless of layperson possession increased between 2013 and 2017.The provision to legalize layperson possession of naloxone was associated with decreased average opioid overdose death rates in 3 states of the West region.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32481373     DOI: 10.1097/MD.0000000000020033

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  6 in total

1.  Gaps in naloxone ownership among people who inject drugs during the fentanyl wave of the opioid overdose epidemic in New York City, 2018.

Authors:  Alexis V Rivera; Michelle L Nolan; Denise Paone; Sidney A Carrillo; Sarah L Braunstein
Journal:  Subst Abus       Date:  2022       Impact factor: 3.984

2.  Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.

Authors:  Randa Abdelal; A Raja Banerjee; Suzanne Carlberg-Racich; Neyla Darwaza; Diane Ito; Jessica Shoaff; Josh Epstein
Journal:  Harm Reduct J       Date:  2022-05-20

3.  A Study on the Efficacy of a Naloxone Training Program.

Authors:  Gillian A Beauchamp; Hoonani M Cuadrado; Seth Campbell; Bennie B Eliason; Chase L Jones; Aaron T Fedor; Lauren Grantz; Paige Roth; Marna Rayl Greenberg
Journal:  Cureus       Date:  2021-11-23

4.  A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.

Authors:  Antoinette L Spector; Carol L Galletly; Erika A Christenson; H Danielle Green Montaque; Julia Dickson-Gomez
Journal:  BMC Public Health       Date:  2022-07-19       Impact factor: 4.135

5.  Understanding opioid overdose risk and response preparedness among people who use cocaine and other drugs: Mixed-methods findings from a large, multi-city study.

Authors:  Jaclyn M W Hughto; Lily K Gordon; Thomas J Stopka; Patricia Case; Wilson R Palacios; Abigail Tapper; Traci C Green
Journal:  Subst Abus       Date:  2021-07-06       Impact factor: 3.984

6.  Geographical Aspects of Recent Trends in Drug-Related Deaths, with a Focus on Intra-National Contextual Variation.

Authors:  Peter Congdon
Journal:  Int J Environ Res Public Health       Date:  2020-11-02       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.